

Experiences with consumer driven care in Europe: An overview

Reinhard Busse, Prof. Dr. med. MPH FFPH

Professor of Health Care Management, Berlin University of Technology

Associate Research Director, European Observatory on Health Systems and Policies



Conflicting roles of the individual

- Consumer
- Patient
- Mandatorily insured/ taxpayer
- Voluntarily insured
- Citizen
- Representative of consumers, patients, insured (e.g. board of sickness fund), citizens (e.g. member of parliament)



Consumer-driven health care?


(Individual) Choice

Shared decision making (in clinical decisions)

(Collective) Participation



- Social health insurance countries in western Europe
- Central and eastern Europe (Semashko to SHI)
- Tax-based systems in western Europe



- to be insured at all Individual choice (Germany, Netherlands above income threshold) Third-party payer - between statutory system and VHI (Germany) - of sickness fund Covered within SHI (Belgium, Czech Republic, benefits Regulator Germany, Netherlands, Slovakia, Switzerland) **Provider 1 Population**

Provider 2

Drug/ device

- to be insured at all Individual choice

(Germany, Netherlands above income threshold) Third-party payer

- between statutory system

and VHI (Germany)

- of sickness fund

within SHI (Belgium,

Czech Republic,

Germany, Nether-

lands, Slovakia,

Switzerland)

Population

- almost everybody gets insured

- NL abolished "no insurance" option

-most Germans with choice

opt for SHI rather than VHI

- movement between funds is limited

but sufficient to worry policy-makers

- choice within SHI requires complicated,

(and disputed) risk adjustment

ovider 2

Drug/ device

Individual choice

Third-party payer

New developments:
,,client-based budget" (NL, Germany)
- financial incentives for
voluntary gatekeeping

Regulator

all SHI countries, most

NHS countries; Sweden, Spain,

CEE only since 1990s

Provider 1

Covered

benefits

without gatekeeping: SHI countries except NL; after gatekeeping: more and more NHS countries, especially in northern and southern Europe


Population


Provider 2


Drug/ device

Individual choice Third-party payer

Co-payment design: - flat (e.g. Spain) Covered - by package size - price-dependent benefits - by effectiveness (France, Italy) - co-payments **Provider 1 Population** (except NL) - more OTC **Provider 2** - reference prices with choice between products, at cheapest level, Drug/ device only for one product? (Belgium)








<< Denmark, Sweden

(Belgium),
Germany,
Netherlands,
Switzerland:
emphasis on
individual choice



UK:
emphasis on
collective
participation

<? CEE countries?>





This presentation and more material can be found on my department's website

http://mig.tu-berlin.de

